Acorda Therapeutics Inc (ACOR): Insiders Are Dumping, Should You?

Page 1 of 2

Acorda Therapeutics Inc (NASDAQ:ACOR) was in 10 hedge funds’ portfolio at the end of the fourth quarter of 2012. ACOR investors should pay attention to a decrease in support from the world’s most elite money managers of late. There were 15 hedge funds in our database with ACOR positions at the end of the previous quarter.

In the financial world, there are plenty of metrics investors can use to track Mr. Market. A duo of the best are hedge fund and insider trading activity. At Insider Monkey, our research analyses have shown that, historically, those who follow the best picks of the best fund managers can outclass the market by a significant amount (see just how much).

Equally as integral, positive insider trading activity is another way to parse down the world of equities. There are plenty of incentives for a bullish insider to get rid of shares of his or her company, but only one, very clear reason why they would initiate a purchase. Various empirical studies have demonstrated the market-beating potential of this tactic if investors know where to look (learn more here).

With all of this in mind, let’s take a peek at the latest action regarding Acorda Therapeutics Inc (NASDAQ:ACOR).

Hedge fund activity in Acorda Therapeutics Inc (NASDAQ:ACOR)

In preparation for this year, a total of 10 of the hedge funds we track held long positions in this stock, a change of -33% from the third quarter. With the smart money’s capital changing hands, there exists a few key hedge fund managers who were boosting their holdings meaningfully.

Of the funds we track, SAC Capital Advisors, managed by Steven Cohen, holds the most valuable position in Acorda SAC CAPITAL ADVISORSTherapeutics Inc (NASDAQ:ACOR). SAC Capital Advisors has a $18.7 million position in the stock, comprising 0.1% of its 13F portfolio. Coming in second is Millennium Management, managed by Israel Englander, which held a $10.2 million position; 0.1% of its 13F portfolio is allocated to the stock. Some other hedge funds with similar optimism include Samuel Isaly’s OrbiMed Advisors, Jim Simons’s Renaissance Technologies and Sean Cullinan’s Point State Capital.

Since Acorda Therapeutics Inc (NASDAQ:ACOR) has faced declining sentiment from the smart money, we can see that there exists a select few hedgies that decided to sell off their entire stakes last quarter. At the top of the heap, Roberto Mignone’s Bridger Management sold off the largest investment of the “upper crust” of funds we monitor, totaling about $19.2 million in stock., and Mark Broach of Manatuck Hill Partners was right behind this move, as the fund dumped about $3.8 million worth. These bearish behaviors are interesting, as aggregate hedge fund interest was cut by 5 funds last quarter.

What do corporate executives and insiders think about Acorda Therapeutics Inc (NASDAQ:ACOR)?

Insider trading activity, especially when it’s bullish, is best served when the company we’re looking at has seen transactions within the past half-year. Over the last six-month time period, Acorda Therapeutics Inc (NASDAQ:ACOR) has experienced zero unique insiders buying, and 7 insider sales (see the details of insider trades here).

Let’s also examine hedge fund and insider activity in other stocks similar to Acorda Therapeutics Inc (NASDAQ:ACOR). These stocks are Synageva BioPharma Corp (NASDAQ:GEVA), Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), Sarepta Therapeutics Inc (NASDAQ:SRPT), ImmunoGen, Inc. (NASDAQ:IMGN), and Nektar Therapeutics (NASDAQ:NKTR). This group of stocks are the members of the biotechnology industry and their market caps match ACOR’s market cap.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 44 percentage points in 21 months Learn how!

Lists

The Top 10 States With Fastest Internet Speeds

10 Best Places to Visit in USA in August

Top 10 Cities to Visit Before You Die

Top 10 Genetically Modified Food In the US

15 Highest Grossing Movies Opening Weekend

5 Best Poker Books For Beginners

10 Strategies Hedge Funds Use to Make Huge Returns

Top 10 Fast Food Franchises to Buy

10 Best Places to Visit in Canada

Best Summer Jobs for Teachers

10 Youngest Hedge Fund Billionaires

Top 10 One Hit Wonders of the 90s

Fastest Growing Cities In America

Top 10 U.S. Cities for Freelancers

Top 9 Most Popular Free iPhone Apps

Top 10 Least Expensive Private Business Schools in the US

Top 15 Most Expensive Countries in the World – 2014

Top Businesses to Invest In

Top 5 Things You Might Be Doing Wrong With Your Business

Top 5 Strategic Technology Trends in 2014

Top Rags to Riches Stories

Parenting Behavior That Promotes Future Leaders

Top 5 Mistakes Made by Small Businesses

Top 5 Most Common and Potentially Devastating Financial Blunders

Top 5 Highest Paying Jobs for Web Designers

Top 6 Most Respected Professions that Also Pay Well

Top 5 Pitfalls Investors Should Avoid

Top 6 Lawyers and Policy Makers Under 30

Top 6 New Year’s Resolutions for Entrepreneurs

Top 7 Locations to Check in on Facebook

Top 5 Mistakes made by Rookie eBay Sellers

Top 7 eBook Publishers in 2013

Top 6 Health Industry Trends in 2014

5 Lessons for Entrepreneurs from Seth Godin

Top 5 Success Tips from Jordan Belfort – the Wolf of Wall Street

Best Master’s in Finance Degree Programs

Top 6 Earning Celebrities Over 50

The most expensive sports to play

Top 7 Earning Celebrities Under 25

Best 7 Online Courses to Take: Free Finance MOOCs

Top 6 Bad Habits that Promote Failure

20 Most Valuable Soccer Teams in the World in 2013

12 Most Expensive Countries for Foreign Students

Top 30 Most Influential Women in the World

Top 20 Most Expensive New Year Eve Shows

Top 5 Best Vocational Careers

Top 10 Jobs for 2014 by Salary Gain (Predictions)

Top 5 Digital Trends for 2014

Top 6 Things You Can Do To Increase Your Productivity

Top 9 Trending Smartphones in 2013

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!